Moës A J
Université Libre de Bruxelles, Pharmaceutics and Biopharmaceutics Laboratory, Brussels, Belgium.
Crit Rev Ther Drug Carrier Syst. 1993;10(2):143-95.
This article begins with a review of gastric emptying, small intestine transit, and colonic transit of drug delivery systems with special attention paid to the different physiological processes involved in stomach emptying and to the cut-off size of nondigestible solids for passage through the gastroduodenal junction during the digestive phase. Then, the proposed means for prolonging the gastric residence time (GRT) of drug delivery systems are reviewed and analyzed with special emphasis on floating (F) dosage forms. The following means are discussed: the use of passage-delaying agents, large single-unit dosage forms, bioadhesive drug delivery systems, "heavy" pellets, and buoyant forms. In the section devoted to bioadhesive forms, the influence of the turnover time of the intestinal mucus gel layer on the performance of mucoadhesive preparations is pointed out to explain the poor results obtained in humans with such peroral products. The use of a specifically designed apparatus for measuring the total force acting vertically on an object immersed in a liquid is presented as a methodology for selecting optimized buoyant formations in vitro. Scintigraphic studies are described in nonfasting human volunteers either in upright or in supine posture, who concurrently were given one optimized F and one nonfloating (NF) hydrophilic matrix capsules of the same size, for three different sizes (small, medium, and large). In upright subjects, the F forms stayed continuously above the gastric contents irrespective of their size, whereas the NF ones sank rapidly after administration and never rose back to the surface thereafter. Consequently, the F forms show prolonged and more reproducible GRTs compared to the NF ones. The significance and extent of this prolongation are the most marked for the small size units (p < 0.001) but gradually lessen as the dosage form size increases (p < 0.05 for the medium size units), to become insignificant for the large size units (p > 0.05). Moreover, there is no significant difference between the mean GRTs of the small, medium, and large F units (p > 0.05). This indirectly confirms that the intragastric buoyancy of the F forms is the main process determining their prolonged GRT and protecting them from random gastric emptying related to antral peristaltism. Thus, their GRT depends mainly on the occurrence of the end point of digestion. To the contrary, the lasting retention of the NF forms in the stomach is only size dependent.(ABSTRACT TRUNCATED AT 400 WORDS)
本文首先回顾了药物递送系统的胃排空、小肠转运和结肠转运,特别关注胃排空过程中涉及的不同生理过程以及消化期不可消化固体通过胃十二指肠连接处的临界尺寸。然后,对延长药物递送系统胃滞留时间(GRT)的建议方法进行了综述和分析,特别强调了漂浮(F)剂型。讨论了以下方法:使用 passage-delaying 剂、大的单一单元剂型、生物粘附性药物递送系统、“重”丸剂和浮力剂型。在关于生物粘附性剂型的部分中,指出了肠粘液凝胶层周转时间对粘膜粘附制剂性能的影响,以解释此类口服产品在人体中取得的不佳结果。介绍了使用专门设计的仪器测量垂直作用于浸入液体中的物体的总力,作为体外选择优化浮力制剂的一种方法。描述了在非禁食的人类志愿者中进行的闪烁扫描研究,这些志愿者处于直立或仰卧姿势,同时给予三种不同尺寸(小、中、大)的一个优化的 F 型和一个相同尺寸的非漂浮(NF)亲水性基质胶囊。在直立受试者中,无论尺寸大小,F 型制剂始终停留在胃内容物上方,而 NF 型制剂给药后迅速下沉,此后再也没有回升到表面。因此,与 NF 型制剂相比,F 型制剂显示出更长且更可重复的 GRT。这种延长的意义和程度在小尺寸单元中最为明显(p < 0.001),但随着剂型尺寸的增加逐渐减小(中尺寸单元 p < 0.05),对于大尺寸单元变得不显著(p > 0.05)。此外,小、中、大 F 型单元的平均 GRT 之间没有显著差异(p > 0.05)。这间接证实了 F 型制剂的胃内浮力是决定其延长 GRT 并保护它们免受与胃窦蠕动相关的随机胃排空影响的主要过程。因此,它们的 GRT 主要取决于消化终点的出现。相反,NF 型制剂在胃中的持久滞留仅取决于尺寸。(摘要截断于400字)